Disclosure Information N. Prokopi: None. M. Heeren: None. I. Milenova: None. K. van Pul: None. T. Muijlwijk: None. M. Arends: None. S. van der Velde: None. K. Vrijland: None. A. van Weverwijk: None. K. de Visser: None. R. van de Ven: None. T. de Gruijl: None.

P09.03 CATHEPSIN S ALTERATIONS INDUCE A TUMOR-PROMOTING IMMUNE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA

¹JA Hildebrand*, ¹D Bararia, ¹S Stolz, ¹S Häbe, ²F Osorio-Barrios, ³MD Bartoschek, ¹E Gaitzsch, ¹V Jurinovic, ⁴K Rautter, ⁵C Ludwig, ³S Bultmann, ³H Leonhardt, ⁵S Eustermann, ⁶K Hopfner, ⁷W Hiddemann, ⁷M Bergwelt, ⁸M Schmidt-Supprian, ⁹MB Sárosi, ¹⁰M Rudelius, ¹V Passerini, ¹¹J Mautner, ¹O Weigert. ¹Experimental leukemia and lymphoma research, LMU, university clinic, Munich, Germany; ²Hematology and Oncology, TUM, Klinikum rechts der Isar, Munich, Germany; ³Department of Biology II, LMU, Center for Integrated Protein Science Munich (CIPSM), Munich, Germany; ⁴Immunanalytics: Research Group Tissue Control of Immunocytes and Core Facility, Helmholtz Zentrum, Munich, Germany; ⁵Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), TUM, Munich, Germany; ⁶Gene Center, LMU, Munich, Germany; ⁷Department of Internal Medicine III, LMU, Munich, Germany; ⁸Hematology and Oncology, Klinikum rechts der Isar, TUM, Munich, Germany; ⁹Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig, Germany; ¹⁰Institute of Pathology, LMU, Munich, Germany; ¹¹Helmholtz Zentrum, Munich, Germany

10.1136/jitc-2020-ITOC7.103

Background By targeted DNA sequencing of 305 diagnostic follicular lymphoma (FL) biopsies, we identified somatic mutations of *Cathepsin S* (CTSS) in 8% of cases (24/305), mostly clustered at Y132 (19/24) converting Y to D (16/19). Another 13% of FL had CTSS amplifications (37/286), associated with higher CTSS expression ($P=0.05$). CTSS is a cysteine protease that is highly expressed in endolysosomes of antigen presenting cells and malignant B-cells. CTSS is involved in proteolytic processing of antigenic peptides for presentation on MHC-II to be recognized by antigen specific CD4⁺ T-cells.¹ CTSS is synthesized as an inactive zymogen, which is converted to its active form by autocatalytic cleavage of the autoinhibitory propeptide (pro-CTSS).

Materials and Methods We used CRISPR/Cas9 to introduce CTSS Y132D into Karpas422, a B-cell lymphoma cell line that harbors the FL hallmark translocation t(14;18). We purified pro-CTSS WT and Y132D and assayed the *in vitro* autocatalytic cleavage over time. We then tested the impact of CTSS on CD4⁺ T-cell activation in co-culture assays, in a previously described *in vivo* model² which we slightly modified to reflect FL-like conditions, and in primary patient samples.

Results Single-cell derived Y132D mutant Karpas422 clones showed >3-fold higher ratios of active CTSS to pro-CTSS (N=4, $P=0.0003$). Immunoprecipitated CTSS Y132D had >3-fold higher *in vitro* substrate cleavage activity compared to CTSS wild type (WT) (N=6, $P=0.001$) which was mediated by an accelerated conversion from pro-CTSS to active CTSS (11 minutes for CTSS Y132D vs 17 minutes for CTSS WT; N=3, $P=0.04$). Molecular dynamics simulations showed that the Y132D mutation shortens the distances by ~2Å between the catalytic triad of active CTSS (C139, H278, N298) and a stretch of amino acids from the proform (L80, G81, D82, S94), which could facilitate intramolecular cleavage. The higher substrate cleavage activity of CTSS Y132D came along with a high capacity to stimulate antigen specific CD4⁺ T cell responses *in vitro* and *in vivo*. Additionally, CTSS overexpression could phenocopy this high CD4⁺ T cell activation. Lastly, we aimed to correlate CTSS aberrations

with clinical outcome in patients who received standard immunochemotherapy (R-CHOP) for advanced FL (N=51 with available CTSS mutation and gene expression data). Compared to all other patients (N=34), patients with CTSS Y132 mutations or CTSS overexpression (N=17) had longer failure free survival ($P=0.012$).

Conclusions Here, we provide biochemical, structural, functional and clinical evidence that aberrant CTSS activity induces a supportive immune microenvironment in FL. We propose that aberrant CTSS activity can elicit a CD4⁺ T-cell driven tumor-promoting immune response, which could be amplified within the microenvironment and substantially impact the biology and clinical course of the disease. Thus, aberrant CTSS activity is a promising biomarker and therapeutic target in FL and potentially also other tumors.

REFERENCES

1. Riese, R.J., et al., Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. *Immunity* 1996; **4**(4): p. 357–66.
2. Kim, K.J., et al., Establishment and characterization of BALB/c lymphoma lines with B cell properties. *J Immunol* 1979; **122**(2): p. 549–54.

Disclosure Information J.A. Hildebrand: None. D. Bararia: None. S. Stolz: None. S. Häbe: None. F. Osorio-Barrios: None. M.D. Bartoschek: None. E. Gaitzsch: None. V. Jurinovic: None. K. Rautter: None. C. Ludwig: None. S. Bultmann: None. H. Leonhardt: None. S. Eustermann: None. K. Hopfner: None. W. Hiddemann: None. M. Bergwelt: None. M. Schmidt-Supprian: None. M.B. Sárosi: None. M. Rudelius: None. V. Passerini: None. J. Mautner: None. O. Weigert: None.

P09.04 ONCOLYTIC H5N1 INFLUENZA STRAIN DISPLAYS SUPERIOR THERAPEUTIC PROPERTIES INDEPENDENT OF IMMUNO-STIMULATORY INTERLEUKIN-2 TRANSGENE EXPRESSION

¹J Kabiljo*, ¹I Kuznetsova, ¹J Homola, ¹S Proding, ^{1,2}J Laengle, ¹M Sachet, ³A Egorov, ^{1,2}M Bergmann. ¹Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria, Vienna, Austria; ²Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria, Vienna, Austria; ³Research Institute of Influenza, Russian Academy of Medical Sciences, Prof. Popova Str. 15/17 196376 St. Petersburg, Russia, St. Petersburg, Russian Federation

10.1136/jitc-2020-ITOC7.104

Background Oncolytic viruses are becoming an integral part of immunological approaches to cancer treatment. Interleukin-2 (IL-2) is known to stimulate cytotoxic T-cells, and might therefore be a reasonable cargo to enhance the therapeutic effect of such viruses. However, IL-2 is also known to promote immunosuppressive regulatory T-cells (T-reg). We investigated the impact of virally expressed IL-2 on induction of regulatory T-cells. We further investigated the effect of virally expressed IL-2 on the therapeutic efficacy of influenza A H1 and H5 subtypes.

Materials and Methods Survival of B16 melanoma xenograft bearing mice upon treatment with various oncolytic influenza viruses was examined. Effect of these viruses on PBMC gathered from 4 young healthy volunteers and murine and human melanoma cell lines was examined utilizing multiple flow cytometry protocols.

Results Viral IL-2 expression did not alter viral growth and was stable up to multiple passages in cell cultures. In human PBMC viral expression of IL-2 did not enhance differentiation